Cybin completes dosing in phase 2 study of cyb003 for the treatment of major depressive disorder

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced the completion of dosing of the final cohort in its phase 2 study of cyb003, a proprietary deuterated psilocybin analog program in development for the potential treatment of major depressive disorder (“mdd”). the cyb003 progra.
CYBN Ratings Summary
CYBN Quant Ranking